| Document |
Document Title |
|
WO/2017/013648A1 |
Provided herein are alpha2- selective Na,K-ATPase inhibitors and prodrugs thereof, characterized by having a cyclic moiety attached to a digoxin or digitoxin derivative, as well as uses thereof in lowering intraocular pressure and in tre...
|
|
WO/2016/204493A1 |
The present invention relates to a novel (1aS,1bS,2S,4S,5aR,6S,6aS)-1a-(hydroxymethyl)-4-methoxy-2-((
(2S,3R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2
H-pyran-2-yl)oxy)octahydrooxireno[2',3':4,5]cyclopenta[1,2-c
]pyran-6-yl 4...
|
|
WO/2016/198485A1 |
The present invention relates to compounds according to general formula (I) with enhanced absorption of UV-B irradiation. The present invention also relates to an UV-B tolerant plant and a method for enhanced production of compounds acco...
|
|
WO/2016/197980A1 |
The present invention relates to the technical field of pharmaceutical chemistry, especially to Baicalin crystal form A, and preparation method and application thereof. The crystal form shows characteristic peaks at X-ray powder diffract...
|
|
WO/2016/192829A1 |
The present invention relates to feed media comprising deep eutectic solvents and/or ionic liquids.
|
|
WO/2016/192830A1 |
The present invention relates to cell culture media compositions comprising deep eutectic solvents and/or ionic liquids.
|
|
WO/2016/183905A1 |
An icarisid compound shown in Formula I. The compound is a natural chemical component of a traditional Chinese medicine (epimedium herb) or a chemically modified product or a totally synthetic product based on these natural products. The...
|
|
WO/2016/180818A1 |
The present invention relates to glycosylating polyphenols via biocatalysis. More specifically the present invention discloses particular mutants of the thermostable sucrose phosphorylase derived from the microorganism Thermoanaerobacter...
|
|
WO/2016/168568A1 |
Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3' -substituted C16 ureas, carbamates...
|
|
WO/2016/154533A1 |
The present invention provides desosamine and mycaminose analogs and nitro sugars and methods for their preparation. The invention also provides methods of cyclizing a compound of Formula (Α') with glyoxal to give a nitro sugar of Formu...
|
|
WO/2016/144833A1 |
Processes and intermediates for preparing fluoroketolide compounds are described herein.
|
|
WO/2016/128401A1 |
The present invention relates to compounds of general formula (I), wherein R1, R2 and (A) take various meanings, pharmaceutical compositions containing them and their use in medicine, particularly for the treatment and/or prophylaxis of ...
|
|
WO/2016/124585A1 |
The present invention relates to a process for the preparation of diosmin from hesperidin. The process involves the oxidation of acylated hesperidin with iodine or bromine in a C2-C4 carboxylic acid medium and subsequent treatment with a...
|
|
WO/2016/112317A1 |
The present invention pertains to prevention of and/or treatment for filariasis. In particular, the present invention pertains to the use of tylosin A and its analogs and derivatives to prevent or treat filarial worm infection and/or dis...
|
|
WO/2016/074221A1 |
Provided are a spinosad heterologous expression strain construction method, a spinosad heterologous expression strain obtained by the method and use thereof in preparing the spinosad heterologous expression strain. The method utilizes a ...
|
|
WO/2016/073756A1 |
The present invention provides nucleoside phosphoramidate compounds of Formula (I), where R1, R2a, R2b, R4, R5a, R5b, Rb5, Rb6 and D are as defined herein. The invention further includes pharmaceutical compositions comprising a compound ...
|
|
WO/2016/073972A1 |
A method of treating cancer in a subject in need thereof is described that includes administering a therapeutically effective amount of a virus or virus-like particle to the subject, wherein the virus particle is nonreplicating and nonin...
|
|
WO/2016/070849A1 |
Provided in the present invention are a class of Lincomycin biosynthetic intermediates and a preparation method and use thereof. Specifically provided are Lincomycin biosynthetic intermediates obtained from the genetic modification of a ...
|
|
WO/2016/063896A1 |
Provided is an ascorbic acid derivative that can be used to obtain a glycoside of which ascorbic acid is the aglycone. The abovementioned derivative is the compound represented by formula (A) (i.e., 2,3,6-tri-O-acyl-ascorbic acid). (In t...
|
|
WO/2016/064007A1 |
The present invention relates to: a method for producing rubusoside from stevioside by using a Lactobacillus plantarum strain, which is a type of Lactobacillus; a composition, to be used in the method, for producing rubusoside, containin...
|
|
WO/2016/056648A1 |
The present invention addresses the problem of providing a simple and versatile method for stabilizing 2-O-α-D-glucosyl-L-ascorbic acid in an acidic aqueous medium. The problem is solved by providing a method for stabilizing 2-O-α-D-gl...
|
|
WO/2016/041195A1 |
Disclosed is a class of flavone glycoside derivatives, compounds of structural general formula (I) described below or pharmaceutically acceptable salts or hydrates thereof, comprising racemates, optical isomers and epimers thereof. Also ...
|
|
WO/2016/040779A1 |
Disclosed are urea derivatives of polyene macrolide antibiotics, other than amphotericin B, comprising a urea-containing substructure represented by wherein R represents hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, aminoalk...
|
|
WO/2016/028233A1 |
The present invention provides a method for determining the presence of a microorganism in a sample using an electrochemically active reporter, wherein the method comprises (a) contacting the sample with an electrochemically active repor...
|
|
WO/2016/027755A1 |
A compound of the following formula [1], which possesses good antimicrobial activity against erythromycin-resistant bacteria, such as resistant pneumococci, streptococci and mycoplasma, against which conventional macrolide antibiotics do...
|
|
WO/2016/019682A1 |
The present invention relates to a chemical synthesis method for phillyrin. The method of the present invention comprises: first dissolving a glycosyl acceptor, phillygenin and a glycosyl donor in an organic solvent and conducting glycos...
|
|
WO/2016/014779A1 |
Provided are antifungal C2'-epi-polyene macrolides with dramatically improved therapeutic index compared to corresponding mycosamine-bearing polyene macrolides. Also provided are methods for making the antifungal C2'-epi-polyene macrolid...
|
|
WO/2016/004848A1 |
A fidaxomicin purification method, comprising: fermenting Actinoplanes sp. HS-16-20 to generate fermented liquid; conducting solid/liquid separation on the fermented liquid, soaking mycelium in an organic solvent, and filtering to obtain...
|
|
WO/2016/005049A1 |
The present invention relates to a compound according to general formula (I), which exhibits bioactivity; methods for the production of the compound; to pharmaceutical compositions comprising one or more of the compound(s); and to the us...
|
|
WO/2015/190587A1 |
Provided is an amphotericin B derivative represented by formula (I). [In formula (I), each symbol is as defined in the description.] The aforesaid compound, which is characterized by having a urea structure, cyclic structure, hydroxyalky...
|
|
WO/2015/175875A1 |
Disclosed is a derivative of amphotericin B (AmB), denoted C2'epiAmB, with an improved therapeutic index over amphotericin B, pharmaceutical compositions comprising the AmB derivative, methods of making the AmB derivative and the pharmac...
|
|
WO/2015/174460A1 |
Provided is an enzyme-specific fluorescent compound capable of being retained in cells, which can emit fluorescence specifically in a target cell, particularly a cell capable of expressing a reporter enzyme such as β-galactosidase, and ...
|
|
WO/2015/169121A1 |
The present invention relates to the field of pharmaceutical synthesis and pharmacology, in particular to a method for preparing a class of quercetin-O-glycoside derivatives and the use thereof in treating lipid metabolism disorders. The...
|
|
WO/2015/156264A1 |
A purpose of the present invention is to provide a novel glucose derivative, which is taken into cells via a membrane sugar transport system and is represented by formula (1). Another purpose of the present invention is to provide an ima...
|
|
WO/2015/153653A1 |
A series of natural products including phyllanthusum, an arylnaphthalene lignan derivative, with anticancer and antitumor and immurtostimulating activity are disclosed. The invention further encompasses methods of adding water solubilizi...
|
|
WO/2015/152145A1 |
The present invention provides a process for producing a crystalline 2-O-α-D-glucosyl-L-ascorbic acid (AG) powder, the process making it possible to more improve the recovery than in conventional processes, shorten the time required for...
|
|
WO/2015/144731A1 |
The invention relates to a method for producing derivatives of O-α-glucosylated flavonoid, comprising at least one step of incubating a glucansucrase with a flavonoid and at least one sucrose, the flavonoid being a flavonoid which is mo...
|
|
WO/2015/140153A1 |
The present invention relates to new polymorphs consiting in crystallines solvates of Tiacumicin B, the solvates being propanol, isopropanol, acetic acid, isopropyl acetate, chlorobenzene and methyl-ethyl-ketone. The present invention al...
|
|
WO/2015/135467A1 |
A sixteen-membered macrolide compound and applications thereof, the compound structure being represented in formula (I), wherein R is CH3 or C2H5. The present compound has a wide range of application in the preparation of chemicals to co...
|
|
WO/2015/138458A1 |
The present invention pertains to derivatives of tylosin A. In particular, the present invention pertains to compounds having a structure of Formula (I). The present invention also pertains to compositions comprising derivatives of tylos...
|
|
WO/2015/133483A1 |
The present invention addresses the problem of providing a novel glucosyl hesperetin in which the unpleasant taste characteristic of conventional glucosyl hesperetin-containing products is significantly reduced, a method for manufacturin...
|
|
WO/2015/127956A1 |
The present invention relates to a process for obtaining Tiacumicin B with a well defined crystal habit and particle size. The process according to the invention comprises repeating cycles of heating and cooling under controlled conditio...
|
|
WO/2015/127955A1 |
The invention refers to acrystalline polymorph form (Form II) of Tiacumicin B and to a process for preparing said solid state form. The process according to this invention is more efficient than methods known in the art and is easily sca...
|
|
WO/2015/127118A1 |
This invention describes a simple, rapid and cost-effective method to isolate bulk quantities of relatively pure and enriched anthocyanidins and other plant bioactives. The method is based on the principle of solubility. Some bioactives ...
|
|
WO/2015/124114A1 |
Disclosed are a phenolic hydroxyl flavone compound semisynthesis method and iodine recovery method, relating to approaches A and B and iodine recovery. In approach A, flavone is dissolved in a pyridine solvent of ethylene glycol or glyce...
|
|
WO/2015/124113A1 |
Provided is a semi-synthesis method for luteolin, galuteolin and luteolin rutinoside. In the method, two steps of dehydrogenation and demethylation are combined into one step, and reaction conditions of dehydrogenation and demethylation ...
|
|
WO/2015/123256A1 |
Compounds, compositions, and methods are described herein for treating diabetes, fatty liver diseases, fibrotic diseases, such as liver and pulmonary fibrosis, and hepatocellular carcinoma.
|
|
WO/2015/116248A1 |
The invention provides nucleoside/nucleotide compounds and pharmaceutically acceptable salts, esters, stereoisomers, tautomers, solvates, and combinations thereof, pharmaceutical compositions comprising. these compounds and the use of th...
|
|
WO/2015/112013A1 |
The present invention relates to a process for attaching an N-acetylgalactosamine- (hetero)arylmoiety to an N-acetylglucosaminemoiety, the process comprising the step of contacting the N-acetylgalactosamine-(hetero)arylmoiety with the N-...
|
|
WO/2015/083554A1 |
The problem addressed by the present invention is to provide a 4G-α-glucosylrutin crystal, a 4G-α-glucosylrutin crystal-containing powder, an application of same as a drug starting material, and applications as a cosmetic product start...
|
